Fisetin and 5‐fluorouracil: Effective combination for PIK3CA ‐mutant colorectal cancer
نویسندگان
چکیده
منابع مشابه
PIK3CA in Colorectal Cancer
PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10-20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of a response to targeted therapy by an...
متن کاملPIK3CA mutation and colorectal cancer precision medicine
The pathogenesis of colorectal adenocarcinoma is driven by the accumulation of multiple genetic and epigenetic aberrations, and is influenced by various endogenous and exogenous factors [1] [Kudryavtseva AV, et al. Oncotarget. 2016;7:53959-53983]. Phosphatidylinositol-4,5-bisphosphonate 3-kinase (PI3K) serves as a major signaling hub downstream of epidermal growth factor receptor (EGFR). The PI...
متن کاملCombined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Aurora A kinase and MEK inhibitors induce different, and potentially complementary, effects on the cell cycle of malignant cells, suggesting a rational basis for utilizing these agents in combination. In this work, the combination of an Aurora A kinase and MEK inhibitor was evaluated in pre-clinical colorectal cancer models, with a focus on identifying a subpopulation in which it might be most ...
متن کاملEffective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer. Here we showed that combined inhibition of PI3K and PARP effectively synergized to inhibit proliferation, survival and invasion in the majority of ovarian cancer...
متن کاملPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review Running Title: PIK3CA Mutation in Colorectal Cancer
Funding: This work was supported by U.S. National Institute of Health [P01CA87969 (to S.E. Hankinson), P01CA55075 (to W.C. Willett), P50CA127003 (to C.S.F.), and R01CA151993 (to S.O.)]; the Bennett Family Fund for Targeted Therapies Research; and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. The content is solely the responsibility of the authors an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Cancer
سال: 2019
ISSN: 0020-7136,1097-0215
DOI: 10.1002/ijc.32367